High Rates of Resistance to Second-Line, PI-Based Regimens in India

Most patients on second-line, protease inhibitor–based antiretroviral therapy had detectable viral loads, and half had evidence of triple-class resistance.

Most HIV-infected patients reside in resource-limited settings without access to routine viral-load and drug-resistance testing. In India, as in Africa, nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens are used as first-line treatment, and protease inhibitor (PI)-based regimens are used as second-line treatment. Little is known, though, about second-line treatment failure in India in terms of rates, resistance profiles, and optimal management.

In the present study, researchers evaluated 107 consecutive patients in southern India who had been receiving second-line, PI-based antiretroviral therapy (typically tenofovir/FTC + boosted atazanavir or boosted indinavir) for at least 6 months. For first-line treatment, most of the…

Reviewing Author

Jonathan Z. Li, MD

High Rates of Resistance to Second-Line, PI-Based Regimens in India

Topics

Reviewing Author